Clinicians may fail to recognize common side effects of drugs like gabapentin — which are frequently prescribed for nerve pain — leading them to prescribe unnecessary medications that… read more.
Digitoxin reduced the risk of a composite of all-cause death and hospitalisation for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF),… read more.
Worldwide, 60 million people suffer from heart failure (HF). Heart failure with preserved ejection fraction (HFpEF) is the most common form of HF, especially among people with obesity… read more.
New research has found that the use of GLP-1 receptor agonists*, a class of medications commonly prescribed for patients with obesity and diabetes, reduces the environmental footprint of… read more.
Researchers report that spironolactone, a medication for high blood pressure and heart failure, does not reduce the risk of heart-related death or hospitalization among patients with kidney failure… read more.
Bayer announced that the FDA has accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for finerenone for the treatment of adult patients with heart… read more.
Patients who have been treated for heart failure and experience an improvement of their pump function, are still at higher risk of heart-related death or hospitalisation if they… read more.
Bayer announced the submission of a marketing authorization application to the Ministry of Health, Labour, and Welfare (MHLW) in Japan, seeking approval of finerenone in adult patients with… read more.
A 240-year-old drug called digoxin could save the National Health Service (NHS) at least £100 million each year when treating older patients with atrial fibrillation and heart failure. … read more.
Bayer announced the submission of a marketing authorization application to the EMA, seeking approval in the EU for the use of finerenone in adult patients with HF with… read more.
About 6.7 million American adults are living with heart failure (HF), and prevalence is expected to reach more than 8 million by 2030.[1] While there is no cure for HF,… read more.
Bayer announced the submission of marketing authorization applications to the FDA and to the Center of Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA), seeking approval… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
